NCCN Guidelines® Insights: Ovarian Cancer, Version 3.2022.

Epithelial ovarian cancer is the leading cause of death from gynecologic cancer in the United States, with less than half of patients living >5 years following diagnosis. The NCCN Guidelines for Ovarian Cancer provide recommendations for the diagnosis, evaluation, treatment, and follow-up for patients with ovarian, fallopian tube, and primary peritoneal cancers. These NCCN Guidelines Insights summarize the panel discussion behind recent important updates to the guidelines, including revised guidance on alternative chemotherapy regimens for patients with advanced age and/or comorbidities, a new algorithm for recurrent low-grade serous carcinoma based on developing research and novel therapeutic agents, and updated language regarding tumor molecular analysis applications in ovarian cancer.

[1]  A. Sood,et al.  The genomic landscape of low-grade serous ovarian/peritoneal carcinoma and its impact on clinical outcomes. , 2022, Gynecologic oncology.

[2]  R. L. Hollis,et al.  Trametinib versus standard of care in patients with recurrent low-grade serous ovarian cancer (GOG 281/LOGS): an international, randomised, open-label, multicentre, phase 2/3 trial , 2022, The Lancet.

[3]  A. Jemal,et al.  Cancer statistics, 2022 , 2022, CA: a cancer journal for clinicians.

[4]  Kylie L. Gorringe,et al.  Genomic analysis of low‐grade serous ovarian carcinoma to identify key drivers and therapeutic vulnerabilities , 2020, The Journal of pathology.

[5]  B. Monk,et al.  MILO/ENGOT-ov11: Binimetinib Versus Physician’s Choice Chemotherapy in Recurrent or Persistent Low-Grade Serous Carcinomas of the Ovary, Fallopian Tube, or Primary Peritoneum , 2020, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[6]  R. Gray,et al.  Dabrafenib and Trametinib in Patients With Tumors With BRAFV600E Mutations: Results of the NCI-MATCH Trial Subprotocol H. , 2020, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[7]  A. Sood,et al.  The role of neoadjuvant chemotherapy in the management of low-grade serous carcinoma of the ovary and peritoneum: Further evidence of relative chemoresistance. , 2019, Gynecologic oncology.

[8]  M. Mouret-Reynier,et al.  EWOC-1: A randomized trial to evaluate the feasibility of three different first-line chemotherapy regimens for vulnerable elderly women with ovarian cancer (OC): A GCIG-ENGOT-GINECO study. , 2019, Journal of Clinical Oncology.

[9]  A. Berchuck,et al.  Invasive Epithelial Ovarian Cancer Survival by Histotype and Disease Stage , 2019, Journal of the National Cancer Institute.

[10]  J. Prat,et al.  Ovarian carcinomas: at least five different diseases with distinct histological features and molecular genetics. , 2018, Human pathology.

[11]  A. Oza,et al.  Safety and Efficacy of Extended Bevacizumab Therapy in Elderly (≥70 Years) Versus Younger Patients Treated for Newly Diagnosed Ovarian Cancer in the International ROSiA Study , 2018, International Journal of Gynecologic Cancer.

[12]  H. Weir,et al.  Disparities in ovarian cancer survival in the United States (2001‐2009): Findings from the CONCORD‐2 study , 2017, Cancer.

[13]  J. Ruterbusch,et al.  Recent Trends in Ovarian Cancer Incidence and Relative Survival in the United States by Race/Ethnicity and Histologic Subtypes , 2017, Cancer Epidemiology, Biomarkers & Prevention.

[14]  A. Secord,et al.  Chemotherapy completion in elderly women with ovarian, primary peritoneal or fallopian tube cancer - An NRG oncology/Gynecologic Oncology Group study. , 2017, Gynecologic oncology.

[15]  D. Bodurka,et al.  Hormonal Maintenance Therapy for Women With Low-Grade Serous Cancer of the Ovary or Peritoneum. , 2017, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[16]  I. Shih,et al.  Primary cytoreductive surgery and adjuvant hormonal monotherapy in women with advanced low-grade serous ovarian carcinoma: Reducing overtreatment without compromising survival? , 2016, Gynecologic oncology.

[17]  F. Chauvin,et al.  Prognostic factors for overall survival in elderly patients with advanced ovarian cancer treated with chemotherapy: Results of a pooled analysis of three GINECO phase II trials. , 2016, Gynecologic oncology.

[18]  Jason D. Wright,et al.  Comorbidities and Risk of Chemotherapy-Induced Peripheral Neuropathy Among Participants 65 Years or Older in Southwest Oncology Group Clinical Trials. , 2016, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[19]  Joshy George,et al.  Whole–genome characterization of chemoresistant ovarian cancer , 2015, Nature.

[20]  Jae-Weon Kim,et al.  Gynecologic Cancer InterGroup (GCIG) Consensus Review for Ovarian and Primary Peritoneal Low-Grade Serous Carcinomas , 2014, International Journal of Gynecologic Cancer.

[21]  D. Katsaros,et al.  Carboplatin plus paclitaxel once a week versus every 3 weeks in patients with advanced ovarian cancer (MITO-7): a randomised, multicentre, open-label, phase 3 trial. , 2014, The Lancet. Oncology.

[22]  B. Weber,et al.  Development of a geriatric vulnerability score in elderly patients with advanced ovarian cancer treated with first-line carboplatin: a GINECO prospective trial. , 2013, Annals of oncology : official journal of the European Society for Medical Oncology.

[23]  J. Prat New insights into ovarian cancer pathology. , 2012, Annals of oncology : official journal of the European Society for Medical Oncology.

[24]  D. Bodurka,et al.  Hormonal therapy for recurrent low-grade serous carcinoma of the ovary or peritoneum. , 2012, Gynecologic oncology.

[25]  K. Kinzler,et al.  Low‐grade serous carcinomas of the ovary contain very few point mutations , 2012, The Journal of pathology.

[26]  J. Thigpen Reclassification of Serous Ovarian Carcinoma by a 2-Tier System: A Gynecologic Oncology Group Study , 2012 .

[27]  Kathleen M. Fairfield,et al.  Completion of adjuvant chemotherapy and use of health services for older women with epithelial ovarian cancer. , 2011, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[28]  Supriya G Mohile,et al.  Predicting chemotherapy toxicity in older adults with cancer: a prospective multicenter study. , 2011, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[29]  D. Armstrong,et al.  Recent progress in the diagnosis and treatment of ovarian cancer , 2011, CA: a cancer journal for clinicians.

[30]  S. Mok,et al.  BRAF mutation is rare in advanced-stage low-grade ovarian serous carcinomas. , 2010, The American journal of pathology.

[31]  A. Sood,et al.  Recurrent low-grade serous ovarian carcinoma is relatively chemoresistant. , 2009, Gynecologic oncology.

[32]  S. Pignata,et al.  A phase II study of weekly carboplatin and paclitaxel as first-line treatment of elderly patients with advanced ovarian cancer. A Multicentre Italian Trial in Ovarian cancer (MITO-5) study. , 2008, Critical reviews in oncology/hematology.

[33]  S. Loibl,et al.  Feasibility, toxicity and quality of life of first-line chemotherapy with platinum/paclitaxel in elderly patients aged >or=70 years with advanced ovarian cancer--a study by the AGO OVAR Germany. , 2006, Annals of oncology : official journal of the European Society for Medical Oncology.

[34]  B. Weber,et al.  Carboplatin/cyclophosphamide or carboplatin/paclitaxel in elderly patients with advanced ovarian cancer? Analysis of two consecutive trials from the Groupe d'Investigateurs Nationaux pour l'Etude des Cancers Ovariens. , 2006, Annals of oncology : official journal of the European Society for Medical Oncology.

[35]  A. Whittemore,et al.  Patterns and Progress in Ovarian Cancer Over 14 Years , 2006, Obstetrics and gynecology.

[36]  A. Sood,et al.  Clinical Behavior of Stage II-IV Low-Grade Serous Carcinoma of the Ovary , 2006, Obstetrics and gynecology.

[37]  B. Weber,et al.  Comprehensive geriatric assessment predicts tolerance to chemotherapy and survival in elderly patients with advanced ovarian carcinoma: a GINECO study. , 2005, Annals of oncology : official journal of the European Society for Medical Oncology.

[38]  Michael T Deavers,et al.  Grading Ovarian Serous Carcinoma Using a Two-Tier System , 2004, The American journal of surgical pathology.

[39]  C. Compton,et al.  AJCC Cancer Staging Manual , 2002, Springer New York.